Login
Companies $ACRV
$1.45 -$0.01 (0.68%) Pre-market
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc.

acrivon.com

What Do They Do?

Develops oncology drug candidates and protein-based tests to identify cancer patients whose tumors may respond to treatment.

How Are They Changing?

Since the FY2025 annual report
  • Nov 6, 2026 Acquired JAK1 and PKCθ programs, adding immunology and inflammation The deal added ACR-525 and a preclinical PKCθ program, with no future milestone or royalty payments.

A dual kinase candidate enters clinical testing The older report described separate preclinical programs targeting these kinases; the latest report describes a dual inhibitor as a clinical-stage asset.

Broader treatment approach for serous tumors The older report planned biomarker-guided treatment across ovarian, endometrial and bladder cancers; the latest report adds serous endometrial cancer arms that do not require biopsy or biomarker stratification.

Who Do They Compete With?

Competes with Boundless Bio, Sierra Oncology, Sentinel Oncology, Astrazeneca/Merck, Zentalis, Debiopharm, Impact Therapeutics, Shouya Holdings, Aprea, BioCity Biopharma, Wigen Biomedicine Technology, HUYA Biomedicines, Bristol Myers Squibb, Repare Therapeutics, Qilu Pharma, Evariste, and Schrödinger

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support